S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
Log in

NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Forecast & News

$0.62
+0.05 (+8.77 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.59
Now: $0.62
$0.64
50-Day Range
$0.45
MA: $0.68
$1.05
52-Week Range
$0.40
Now: $0.62
$6.29
Volume218,044 shs
Average Volume436,090 shs
Market Capitalization$7.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMPI
CUSIPN/A
Phone858-350-4364

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.13) per share

Profitability

Net Income$-8,050,000.00

Miscellaneous

Employees4
Market Cap$7.07 million
Next Earnings Date2/10/2020 (Estimated)
OptionableNot Optionable

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.


DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

Shares of DelMar Pharmaceuticals reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) issued its quarterly earnings data on Tuesday, September, 10th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.59. View DelMar Pharmaceuticals' Earnings History.

When is DelMar Pharmaceuticals' next earnings date?

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for DelMar Pharmaceuticals.

What is the consensus analysts' recommendation for DelMar Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DelMar Pharmaceuticals.

Has DelMar Pharmaceuticals been receiving favorable news coverage?

News articles about DMPI stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for DelMar Pharmaceuticals.

Are investors shorting DelMar Pharmaceuticals?

DelMar Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 241,800 shares, an increase of 270.3% from the October 31st total of 65,300 shares. Based on an average daily volume of 568,300 shares, the days-to-cover ratio is currently 0.4 days. Currently, 9.9% of the company's shares are short sold. View DelMar Pharmaceuticals' Current Options Chain.

Who are some of DelMar Pharmaceuticals' key competitors?

What other stocks do shareholders of DelMar Pharmaceuticals own?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 66)
  • Mr. Jeffrey A. Bacha, Founder (Age 51)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)
  • Mr. Scott Praill CA, CPA, BSc, CFO & Sec. (Age 52)

Who are DelMar Pharmaceuticals' major shareholders?

DelMar Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Sabby Management LLC (8.35%). View Institutional Ownership Trends for DelMar Pharmaceuticals.

Which major investors are buying DelMar Pharmaceuticals stock?

DMPI stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for DelMar Pharmaceuticals.

How do I buy shares of DelMar Pharmaceuticals?

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DMPI stock can currently be purchased for approximately $0.62.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $7.07 million. The company earns $-8,050,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe.View Additional Information About DelMar Pharmaceuticals.

What is DelMar Pharmaceuticals' official website?

The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com/.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected]


MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  500
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe DMPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: 52- Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel